Key statistics
On Friday, argenx SE (ARGX:NSQ) closed at 564.59, 23.43% above the 52 week low of 457.42 set on Jul 22, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 572.40 |
---|---|
High | 575.48 |
Low | 563.29 |
Bid | 520.00 |
Offer | 570.00 |
Previous close | 572.71 |
Average volume | 413.65k |
---|---|
Shares outstanding | 61.20m |
Free float | 60.88m |
P/E (TTM) | 35.61 |
Market cap | 34.94bn USD |
EPS (TTM) | 16.08 USD |
Data delayed at least 15 minutes, as of Jul 18 2025 21:00 BST.
More ▼
- argenx Advances Clinical Development of ARGX-119 in Congenital Myasthenic Syndromes
- argenx Announces European Commission Approval of VYVGART Subcutaneous Injection for Chronic Inflammatory Demyelinating Polyneuropathy
- argenx Presents New Efgartigimod Data at EULAR 2025 Highlighting Positive Phase 2 Proof-of-Concept Results in Myositis and Sjogren’s Disease
- argenx to Present at Goldman Sachs 46th Annual Global Healthcare Conference
- argenx Announces Results of Annual General Meeting of Shareholders
- argenx Reports First Quarter 2025 Financial Results and Provides Business Update
- argenx to Present at BofA Securities 2025 Health Care Conference
- argenx to Report First Quarter 2025 Financial Results and Business Update on May 8, 2025
- argenx Announces Positive CHMP Opinion for VYVGART (efgartigimod alfa) Subcutaneous Injection for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
- argenx Announces Annual General Meeting of Shareholders on May 27, 2025
More ▼